Becton Dickinson's jet lands in El Paso following recent FDA warning letter

Becton Dickinson's Dassault Falcon 7X departed Baltimore/Washington International Airport on May 6, 2026, touching down at El Paso International four hours and forty minutes later after a steady cruise at 43,000 feet. The flight, traced via tail number N294X, marked a swift return to the Southwest for the New Jersey-based company, whose headquarters overlook the recurring rhythm of executive travel.

The timing aligns with fallout from a U.S. Food and Drug Administration warning letter issued April 30, 2026, to BD's CareFusion subsidiary at its El Paso manufacturing site on Northwestern Drive. The letter, stemming from an October 2025 inspection, cited deficiencies in quality systems for medical devices produced there, including the globally used ChloraPrep antiseptic. As BD works to rectify these issues—per the FDA's public notice—high-level visits to the plant underscore the urgency of compliance in an industry where lapses can halt production lines overnight.

This trip fits a pattern of shuttling between Becton Dickinson's Franklin Lakes base and El Paso, where it employs hundreds in biosciences operations. Recent legs include a May 5 hop from El Paso to New Jersey and a May 4 local repositioning near the border city, suggesting ongoing oversight amid the regulatory scrutiny. While El Paso isn't among the company's routine international hubs like London or Tokyo, its domestic facilities demand the same jet-set attention.